IQVIA’s Doug Long: Adalimumab Biosimilars Provide More Opportunity for Price Discounts

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

The rapidly increasing prescriptions for expensive specialty medications, rather than their price growth, are the primary driver of escalating dermatology Medicare Part D expenditures, necessitating policies that balance innovation, access, and affordability.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Investigators sought to measure and attribute out-of-pocket costs to cancer stage and by diagnosis.

According to the American Medical Association, blame for the ongoing physician shortage may lie with overly burdensome administrative processes, an antiquated Medicare payment system, and lack of education for residents in primary care and psychiatry.